Edgar Filing: WELCH DANIEL G - Form 4

Form 4 July 21, 2017 FORM 4 UNITED STATES SECURITIES AND EXCHAINGE COMMISSION Check this box if no longer subject to subject to subject to section 16. Form 3 of both pations may continue. Section 17(a) of the PUBIC Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1935 or Section 1(b). (Print or Type Responses) 1. Name and Address of Reporting Person 1(b). (Print or Type Responses) 1. Name and Address of Reporting Person 1(b). (Print or Type Responses) 1. Name and Address of Reporting Person 1(b). (Print or Type Responses) 1. Name and Address of Reporting Person 1(b). (Print or Type Responses) 1. Name and Address of Reporting Person 1(b). (Print or Type Responses) 1. Name and Address of Reporting Person 1(b). (Print or Type Responses) 1. Name and Address of Reporting Person 1(b). (Print or Type Responses) 1. Name and Address of Reporting Person 1(b). (Print or Type Responses) 1. Name and Address of Reporting Person 1(b). (Print or Type Responses) 1. Name and Address of Reporting Person 1(b). (Print or Type Responses) 1. Name and Address of Reporting Person 1. Name and Address of Reporting Person 1. Name and Address of Reporting Person 1. And the Address of Reporting Person 1. And the Address of Reporting Person 1. And the Public Utility Holding Company Person 1. And the Address of Reporting Person 1. And the Public Person 1. And the	WELCH DA	ANIEL G											
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB APPROVAL Momber: 3235-0287 Check this box if no longer subject to Section 16 or Form 4 or Form 4 or Form 5 or Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, obligations may continue. Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 1(b). StateMent of Securities Exchange Act of 1934, obligations may continue. Section 17(a) of the Public Utility Holding Company Act of 1940 1(b). State Parame and Ticker or Trading Symbol INTERCEPT PHARMACEUTICALS INC [ICPT] Stateinship of Reporting Person(s) to Issuer (Last) (First) (Middle) 3. Date of Earliest Transaction (Month/Day/Year) Stelationship of Reporting Person(s) to Issuer (Last) (First) (Middle) 3. Date of Earliest Transaction (Month/Day/Year) -X_Director below) -00For opering Coll or the opering Person (City) (Street) 4. If Amendment, Date Original Filed(Month/Day/Year) 6. Individual or Joint/Group Filing(Check Applicable Line) -V_Form filed by More thun One Reporting Person (City) (Street) 2.0 Deemed 2.0 Deemed 3. 4. Scurities Acquired, Joppsoed of, Or meneficially Person 6. Amount of Scurities Acquired, Month/Day/Year) 6. Amount of Scurities Acquired, Ownership Indirect Person (City) (Street) 2.0 Deemed 2.0 Demeter (J) (Month/Day/Year) 3. 4. Scurities Acquired or Code (Y Amount (D) Price 5. Amount of Code (Y Amount (D)	Form 4												
Common 0720/2017 Support 2. Issuer Name and Ticker or Trading Symbol S. Relationship of Reporting Person. 0.5 (if no longer subject to the section 16. STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES State area area and the section 16. State area area and the section 16. State area area and the section 16. State area area and the section 17. State area area and the section 17. State area and the section 17. State area and the section 16. State area and the section 19.5 State area and the section 19.5 State area and the section 19.5 State area are area and the section 19.5 State area area are area are area are area are are	July 21, 201	7											
Check this box if no longer subject to Section 16. Form 4 or Form 5 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, obligations may continue. Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940 1(b). (Print or Type Responses) 1. Name and Address of Reporting Person 1/2, 2. Issuer Name and Ticker or Trading Symbol INTERCEPT (Last) (First) (Middle) 3. Date of Earliest Transaction (Month/Day/Year) (Coto INTERCEPT PHARMACEUTICALS, INC, 10 HUDSON YARD, FLOOR 37 (City) (State) (Zip) Table 1 - Non-Derivative Securities Acquired (City) (State) (Zip) Table 1 - Non-Derivative Securities Acquired (City) (State) (Zip) Table 1 - Non-Derivative Securities Acquired (City) (State) (Zip) Table 1 - Non-Derivative Securities Acquired (Month/Day/Year) (Instr. 3) (Month/Day/Year) (Instr. 4) (Month/Day/Year)	FORM	4	~							OMB AF	PROVAL		
Check this box if no longer subject to Section 16. STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Expires: January 31, 2005 Form 4 or Form 5 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, obligations may continue. Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 10(b). Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 17(a) of the Public Utility Holding Company Act of 1940 1(b). Section 17(a) of the Public Utility Holding Company Act of 1940 1(b). (Print or Type Responses) 1. Name and Address of Reporting Person 1 2. Issuer Name and Ticker or Trading Symbol 5. Relationship of Reporting Person(s) to Issuer (Last) (First) (Middle) 3. Date of Earliest Transaction (Month/Day/Year)		• • UNITED	STATES					NGE C	OMMISSION	-	3235-0287		
abject of subject of Section 16. STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF Subject of Section 16. Total average burden hours per response 2005 Form 4 or Form 5 obligations may continue. Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, obligations section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940 1(b). Section 17(a) of the Public Utility Holding Company Act of 1940 1(b). (Print or Type Responses) 1. Name and Address of Reporting Person 1 (Month/Day/Year) 2. Issuer Name and Ticker or Trading Symbol 5. Relationship of Reporting Person(s) to Issuer (Last) (First) (Middle) 3. Date of Earliest Transaction (Month/Day/Year) -X_Director Officer (give tile below) -10% Owner 						, 2101 20	• • •				January 31,		
Section 16. Form 4 or Form 4 or Form 5 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, obligations Sec Instruction 1(b). (Print or Type Responses) 1. Name and Address of Reporting Person ¹ 2. Issuer Name and Ticker or Trading Symbol INTERCEPT PHARMACEUTICALS INC [ICPT] (Last) (First) (Middle) 3. Date of Earliest Transaction (Month/Day/Year) (Month/Day/Year) C/O INTERCEPT PHARMACEUTICALS, INC, 10 HUDSON YARD, FLOOR 37 (Street) 4. If Amendment, Date Original Filed(Month/Day/Year) (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned I.Title of 2. Transaction Date 2A. Deemed 1.Title of 2. Transaction Date 2A. Deemed I.Title of 2. Transaction Date 3. 4. Securities Acquired, Disposed of, or Beneficially Owned I.Title of Code (Instr. 3, 4 and 5) (Month/Day/Year) (Instr. 4) (Month/Day/Year)			AENT OF	CHAN	GES IN	BENEF	ICIA	LOWN	NERSHIP OF	•	2005		
Form 4 or Form 5 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, obligations may continue. Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue. Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue. Section 17(a) of the Investment Company Act of 1940 0.5 (Print or Type Responses) 30(h) of the Investment Company Act of 1940 5. Relationship of Reporting Person(s) to Issuer 1. Name and Address of Reporting Person. [±] 2. Issuer Name and Ticker or Trading Symbol 5. Relationship of Reporting Person(s) to Issuer (Print or Type Responses) 2. Issuer Name and Ticker or Trading 5. Relationship of Reporting Person(s) to Issuer (Last) (First) (Middle) 3. Date of Earliest Transaction (Month/Day/Year)		0		-			-						
Form 5 obligations may continue. See Instruction 10(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1935 or Section 30(h) of the Investment Company Act of 1936. (Print or Type Responses) 30(h) of the Investment Company Act of 1940 1. Name and Address of Reporting Person * WELCH DANIEL G 2. Issuer Name and Ticker or Trading Symbol 5. Relationship of Reporting Person(s) to Issuer (Last) (First) (Middle) 3. Date of Earliest Transaction (Month/Day/Year) 5. Relationship of Reporting Person(s) to Issuer (Last) (First) (Middle) 3. Date of Earliest Transaction (Month/Day/Year) -X													
obligations may continue. See Instruction 1(b). Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940 1(b). (Print or Type Responses) 30(h) of the Investment Company Act of 1940 1(b). 1. Name and Address of Reporting Person* 2. Issuer Name and Ticker or Trading Symbol INTERCEPT PHARMACEUTICALS INC [ICPT] 5. Relationship of Reporting Person(s) to Issuer (Last) (First) (Middle) 3. Date of Earliest Transaction (Month/Day/Year) -X Director below) 10% Owner 		Filed pur	suant to S	ection 1	6(a) of th	e Securi	ties E	Exchange	e Act of 1934,				
See Instruction 1(b). 30(h) of the Investment Company Act of 1940 (Print or Type Responses) 2. Issuer Name and Ticker or Trading Symbol 5. Relationship of Reporting Person(s) to Issuer (Print or Type Responses) 2. Issuer Name and Ticker or Trading Symbol 5. Relationship of Reporting Person(s) to Issuer (Last) (First) (Middle) 3. Date of Earliest Transaction (Month/Day/Year)		ons Section 17(-		1			
1(b). (Print or Type Responses) 1. Name and Address of Reporting Person ⁺ WELCH DANIEL G 2. Issuer Name and Ticker or Trading Symbol INTERCEPT PHARMACEUTICALS INC [ICPT] 5. Relationship of Reporting Person(s) to Issuer (Last) (First) (Middle) 3. Date of Earliest Transaction (Month/Day/Year) $($			30(h)	of the In	vestment	Compar	ny Ac	t of 194	0				
1. Name and Address of Reporting Person.* 2. Issuer Name and Ticker or Trading Symbol 5. Relationship of Reporting Person(s) to Issuer WELCH DANIEL G Symbol INTERCEPT PHARMACEUTICALS INC [ICPT] (Check all applicable) (Last) (First) (Middle) 3. Date of Earliest Transaction (Month/Day/Year) -X_Director -10% Owner C/O INTERCEPT 07/20/2017 07/20/2017 -X_Director -00fficer (give title below) -00fficer (specify below) VBW YORK, NY 10001 4. If Amendment, Date Original Filed(Month/Day/Year) 6. Individual or Joint/Group Filing(Check Applicable Line) -X_Form filed by More than One Reporting Person Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired Scurity 5. Amount of Ownership (Month/Day/Year) 6. Amount of Ownership Code 6. Stanount of Ownership Code 6. Mount of Ownership Following 7. Nature of Downership Following (Instr. 3) 2. Transaction Date any 3. 4. Securities Acquired Owner (Instr. 4) 5. Amount of Ownership Following 6. 7. Nature of Downership Following (Instr. 4) (A) or Code (Instr. 8) (A) or Code 5. Amount of Ownership 6. 7. Nature of Downership (A) Common (D) or Ownership (Instr.													
1. Name and Address of Reporting Person.* 2. Issuer Name and Ticker or Trading Symbol 5. Relationship of Reporting Person(s) to Issuer WELCH DANIEL G Symbol INTERCEPT PHARMACEUTICALS INC [ICPT] (Check all applicable) (Last) (First) (Middle) 3. Date of Earliest Transaction (Month/Day/Year) -X_Director -10% Owner C/O INTERCEPT 07/20/2017 07/20/2017 -X_Director -00fficer (give title below) -00fficer (specify below) VBW YORK, NY 10001 4. If Amendment, Date Original Filed(Month/Day/Year) 6. Individual or Joint/Group Filing(Check Applicable Line) -X_Form filed by More than One Reporting Person Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired Scurity 5. Amount of Ownership (Month/Day/Year) 6. Amount of Ownership Code 6. Stanount of Ownership Code 6. Mount of Ownership Following 7. Nature of Downership Following (Instr. 3) 2. Transaction Date any 3. 4. Securities Acquired Owner (Instr. 4) 5. Amount of Ownership Following 6. 7. Nature of Downership Following (Instr. 4) (A) or Code (Instr. 8) (A) or Code 5. Amount of Ownership 6. 7. Nature of Downership (A) Common (D) or Ownership (Instr.													
WELCH DANIEL G Symbol INTERCEPT PHARMACEUTICALS INC [ICPT] (Last) (First) (Middle) 3. Date of Earliest Transaction (Month/Day/Year) C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARD, FLOOR 37 (Street) 4. If Amendment, Date Original Filed(Month/Day/Year) (Street) 4. If Amendment, Date Original Filed(Month/Day/Year) Applicable Line) 	(Print or Type l	Responses)											
WELCH DANIEL G Symbol INTERCEPT PHARMACEUTICALS INC [ICPT] (Last) (First) (Middle) 3. Date of Earliest Transaction (Month/Day/Year) C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARD, FLOOR 37 (Street) 4. If Amendment, Date Original Filed(Month/Day/Year) (Street) 4. If Amendment, Date Original Filed(Month/Day/Year) Applicable Line) 	1 NT 1 4		D *						5 0 1 (1 1 6				
INTERCEPT PHARMACEUTICALS INC [ICPT] (Check all applicable) (Last) (First) (Middle) 3. Date of Earliest Transaction (Month/Day/Year) -X_Director (Month/Day/Year) -10% Owner (Diffecr (give tile) -10% Owner (Diffecr (give tile) C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARD, FLOOR 37 07/20/2017			Person_		r Name and	Ticker or	Tradi	ng					
PHARMACEUTICALS INC [ICPT] (Check all applicable) (Last) (First) (Middle) 3. Date of Earliest Transaction (Month/Day/Year) X	WELCH DA	CEDT											
(Last) (First) (Middle) 3. Date of Earliest Transaction (Month/Day/Year)								ICDTI	(Check all applicable)				
C/O INTERCEPT (Month/Day/Year) Officer (give title below) Other (specify below) PHARMACEUTICALS, INC., 10 07/20/2017 below) below) below) (Street) 4. If Amendment, Date Original Filed(Month/Day/Year) 6. Individual or Joint/Group Filing(Check Applicable Line) NEW YORK, NY 10001 Filed(Month/Day/Year) Applicable Line) -X_ Form filed by One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired 5. Amount of Securities 6. 7. Nature of Securities 1. Title of Security 2. Transaction Date Any (Month/Day/Year) 3. 4. Securities Acquired (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned 6. 7. Nature of Ownership Indirect (Instr. 3) (Month/Day/Year) (Instr. 8) (Instr. 3, 4 and 5) Securities Beneficially Owned (Instr. 4) Ownership Indirect (Month/Day/Year) Code V Amount (D) Price (Instr. 4) Transaction(s) (Instr. 4) (Instr. 4)							inc į						
C/O INTERCEPT 07/20/2017 PHARMACEUTICALS, INC., 10 HUDSON YARD, FLOOR 37 (Street) 4. If Amendment, Date Original Filed(Month/Day/Year) 6. Individual or Joint/Group Filing(Check Applicable Line) .X. Form filed by One Reporting Person .X. Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of 2. Transaction Date 2A. Deemed any (Month/Day/Year) 5. Amount of 6. 7. Nature of Security (Month/Day/Year) Execution Date, if any (Month/Day/Year) (Instr. 3) (Month/Day/Year) (Instr. 8) (Month/Day/Year) (Instr. 8) Code V Amount (D) Price (Instr. 3 and 4)	(Last)	(First) (1	Middle)			ransaction							
PHARMACEUTICALS, INC., 10 HUDSON YARD, FLOOR 37 4. If Amendment, Date Original Filed(Month/Day/Year) 6. Individual or Joint/Group Filing(Check Applicable Line) -X_ Form filed by More than One Reporting Person Form filed by More than One Reporting Person Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security 2. Transaction Date (Month/Day/Year) 3. 4. Securities Acquired Transactior(A) or Disposed of (D) Code 5. Amount of Securities (Instr. 3) 6. 7. Nature of Indirect (Instr. 3) (Month/Day/Year) 2A. Deemed (Month/Day/Year) 3. 4. Securities Acquired (Instr. 8) 5. Amount of Securities (Instr. 8) 6. 7. Nature of Indirect (I) (Instr. 4) Common 07/20/2017 S(1) 217 D \$ 3.710 D	CIO NITED	CEDT			-								
HUDSON YARD, FLOOR 37 (Street) 4. If Amendment, Date Original Filed(Month/Day/Year) 6. Individual or Jourdon prilocological Applicable Line) -X_ Form filed by One Reporting Person 			7 10	0//20/2	017								
(Street) 4. If Ame-Idment, Date Original Filed(Month/Day/Year) 6. Individual or Joi-t/Group Filling(Check Applicable Line) -X. Form filed by One Reporting Person -Form filed by One Reporting Person -Form filed by One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired Security (Instr. 3) 5. Amount of Security (Month/Day/Year) 6. 6. 7. Nature of Indirect Indirect Indirect Indirect (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. 4. Securities Acquired Transactior(A) or Disposed of (D) Code 5. Amount of Security (Instr. 3, 4 and 5) 6. 7. Nature of Indirect (I) Owneed 7. Nature of Indirect (I) (Instr. 4) Common 07/20/2017 S(1) 217 D \$ 3.710 D													
Filed(Month/Day/Year) Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned Owned 1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. 4. Securities Acquired Transaction(A) or Disposed of (D) Code (Instr. 3, 4 and 5) 5. Amount of Securities 6. 7. Nature of Ownership Owned (D) or Ownership Indirect (Instr. 4) 8 6. 7. Nature of Ownership Code V Amount (D) Price 6. 7. Nature of Ownership 1. Indirect Code V Amount (D) P (Instr. 4) 1. Transaction(s) 6. 7. Nature of Ownership Indirect (I) (Instr. 4) Code (Instr. 8) Form file by Owner 6. 7. Nature of Ownership Code V Amount (D) Price (Instr. 4) 1. 1. Common 07/20/2017 S(1) 217 D \$ 3.710 D	HUDSON .)/										
NEW YORK, NY 10001		(Street)			-								
NEW YORK, NY 10001				Filed(Mo	nth/Day/Year	.)			•••				
(City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. 4. Securities Acquired Transaction(A) or Disposed of (D) (Instr. 3) 5. Amount of Securities Beneficially Form: Direct Beneficial Owned 6. 7. Nature of Ownership Indirect (Instr. 3) (Month/Day/Year) (Month/Day/Year) 3. 4. Securities Acquired Transaction(A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Form: Direct Beneficial Owned 6. 7. Nature of Ownership Indirect (I) (Instr. 4) (Month/Day/Year) (Month/Day/Year) (Instr. 8)	NEW YOR	K NY 10001											
1. Title of Security (Instr. 3)2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3.4. Securities Acquired Transactior(A) or Disposed of (D) Code5. Amount of Securities6.7. Nature of IndirectIndirect Security (Instr. 3)3.4. Securities Acquired Transactior(A) or Disposed of (D) Code5. Amount of Securities6.7. Nature of IndirectIndirect Beneficially (Month/Day/Year)3.4. Securities Acquired Transactior(A) or Disposed of (D) (Instr. 3, 4 and 5)5. Amount of Securities6.7. Nature of OwnershipIndirect Following Or Code V Amount (D)7.1.1.1.1.Common O7/20/20175.3.2.7.0.		K , W 10001							Person				
Security (Instr. 3) (Month/Day/Year) Execution Date, if any Transactior(A) or Disposed of (D) Code Securities Ownership Indirect (Instr. 3) (Month/Day/Year) (Month/Day/Year) (Instr. 3, 4 and 5) Securities Beneficially Ownership Beneficially (Month/Day/Year) (Month/Day/Year) (Instr. 8) (Instr. 8) Owned (D) or Ownership (A) or Or Or Indirect (I) (Instr. 4) (A) or Or (Instr. 3 and 4) (Instr. 3 and 4) Common 07/20/2017 S(1) 217 D \$ 3 710 D	(City)	(State)	(Zip)	Tabl	le I - Non-E	Derivative	Secur	ities Acqu	uired, Disposed of,	or Beneficiall	y Owned		
(Instr. 3) any (Month/Day/Year) Code (Instr. 8) (Instr. 3, 4 and 5) (Instr. 8) Beneficially Owned (D) or Following Reported Transaction(s) (Instr. 4) Form: Direct (D) or (Instr. 4) Beneficially (D) or (Instr. 4) (A) or Code V Amount (D) or Code V Amount (D) (D) Price Form: Direct (D) or (Instr. 4) Beneficially (D) or (Instr. 4)								-			7. Nature of		
(Month/Day/Year) (Instr. 8) (Month/Day/Year) (Instr. 8) (A) or Code V Amount (D) Price Common 07/20/2017 (Month/Day/Year) (Instr. 8) (Instr. 4) (Instr. 4		(Month/Day/Year)		Date, if									
Common 07/20/2017 Code V Amount (D) Price Following Indirect (I) (Instr. 4) (A) Following Indirect (I) (Instr. 4) (Instr. 4)	· · · ·			. , , ,									
Common 07/20/2017 Code V Amount (D) Price (Instr. 4) Code V Amount (D) Price 3 710 D				ay/1cal)	(msu. o)						•		
$\begin{array}{c} \text{or} \\ \text{Code V Amount (D)} \\ \text{Frice} \end{array} \qquad (Instr. 3 and 4) \\ \text{Common} \\ 07/20/2017 \\ \text{S}^{(1)} \\ 217 \\ \text{D} \\ \text{S} \\ 3710 \\ \text{D} \\ \text{D} \\ \text{D} \\ \text{O} \\ $							(A)		Reported		. ,		
$\begin{array}{c} \text{Code V Amount (D) Price} \end{array} (11547.5 \text{ and 4}) \\ \text{Common} 07/20/2017 \qquad \qquad$													
(1/1/1)/(1/1/1) $(1/1)$ $(1/1)/(1/1)$ $(1/1)/(1/1)$					Code V	Amount		Price	(Instr. 3 and 4)				
Stock 5.726777 5.710 D		07/20/2017			S (1)	217	D		3 710	D			
	Stock	0112012011			<u> </u>	217	D	126.76	5,710	2			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: WELCH DANIEL G - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. onNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		Secur	int of rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owna Follo Repo Trans (Instr
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Address		Relationships						
FB		Director	10% Owner	Officer	Other			
WELCH DANIEL G C/O INTERCEPT PHARMACEUTICAI 10 HUDSON YARD, FLOOR 37 NEW YORK, NY 10001	LS, INC.	Х						
Signatures								
/s/ Bryan Yoon, as attorney-in-fact	07/21/2017	7						

**Signature of Reporting Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person.

Date

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.